Nanni Cristina, Zanoni Lucia, Pultrone Cristian, Schiavina Riccardo, Brunocilla Eugenio, Lodi Filippo, Malizia Claudio, Ferrari Matteo, Rigatti Patrizio, Fonti Cristina, Martorana Giuseppe, Fanti Stefano
Nuclear Medicine, AOU Policlinico S.Orsola-Malpighi, Via Massarenti, 9 40138, Bologna, Italy.
Urology, AOU Policlinico S.Orsola-Malpighi, Bologna, Italy.
Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1601-10. doi: 10.1007/s00259-016-3329-1. Epub 2016 Mar 10.
To compare the accuracy of (18)F-FACBC and (11)C-choline PET/CT in patients radically treated for prostate cancer presenting with biochemical relapse.
This prospective study enrolled 100 consecutive patients radically treated for prostate cancer and presenting with rising PSA. Of these 100 patients, 89 were included in the analysis. All had biochemical relapse after radical prostatectomy (at least 3 months previously), had (11)C-choline and (18)F-FACBC PET/CT performed within 1 week and were off hormonal therapy at the time of the scans. The two tracers were compared directly in terms of overall positivity/negativity on both a per-patient basis and a per-site basis. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy were calculated for both the tracers; follow-up at 1 year (including correlative imaging, PSA trend and pathology when available) was considered as the standard of reference.
In 51 patients the results were negative and in 25 patients positive with both the tracers, in eight patients the results were positive with (18)F-FACBC but negative with (11)C-choline, and in five patients the results were positive with (11)C-choline but negative with (18)F-FACBC. Overall in 49 patients the results were false-negative (FN), in two true-negative, in 24 true-positive (TP) and in none false-positive (FP) with both tracers. In terms of discordances between the tracers: (1) in one patient, the result was FN with (11)C-choline but FP with (18)F-FACBC (lymph node), (2) in seven, FN with (11)C-choline but TP with (18)F-FACBC (lymph node in five, bone in one, local relapse in one), (3) in one, FP with (11)C-choline (lymph node) but TP with (18)F-FACBC (local relapse), (4) in two, FP with (11)C-choline (lymph nodes in one, local relapse in one) but FN with (18)F-FACBC, and (5) in three, TP with (11)C-choline (lymph nodes in two, bone in one) but FN with (18)F-FACBC. With (11)C-choline and (18)F-FACBC, sensitivities were 32 % and 37 %, specificities 40 % and 67 %, accuracies 32 % and 38 %, PPVs 90 % and 97 %, and NPVs 3 % and 4 %, respectively. Categorizing patients by PSA level (<1 ng/ml 28 patients, 1 - <2 ng/ml 28 patients, 2 - <3 ng/ml 11 patients, ≥3 ng/ml 22 patients), the number (percent) of patients with TP findings were generally higher with (18)F-FACBC than with (11)C-choline: six patients (21 %) and four patients (14 %), eight patients (29 %) and eight patients (29 %), five patients (45 %) and four patients (36 %), and 13 patients (59 %) and 11 patients (50 %), respectively.
(18)F-FACBC can be considered an alternative tracer superior to (11)C-choline in the setting of patients with biochemical relapse after radical prostatectomy.
比较¹⁸F-FACBC和¹¹C-胆碱PET/CT在接受前列腺癌根治性治疗后出现生化复发患者中的准确性。
本前瞻性研究纳入了100例连续接受前列腺癌根治性治疗且PSA升高的患者。在这100例患者中,89例纳入分析。所有患者均在前列腺癌根治术后(至少3个月前)出现生化复发,在1周内接受了¹¹C-胆碱和¹⁸F-FACBC PET/CT检查,且在扫描时未接受激素治疗。对两种示踪剂在每位患者和每个部位的总体阳性/阴性情况进行直接比较。计算两种示踪剂的敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性;将1年的随访(包括相关影像学检查、PSA趋势以及如有可用的病理检查)视为参考标准。
51例患者两种示踪剂检查结果均为阴性,25例患者两种示踪剂检查结果均为阳性,8例患者¹⁸F-FACBC检查结果为阳性而¹¹C-胆碱检查结果为阴性,5例患者¹¹C-胆碱检查结果为阳性而¹⁸F-FACBC检查结果为阴性。总体而言,49例患者检查结果为假阴性(FN),2例为真阴性,24例为真阳性(TP),两种示踪剂检查均无假阳性(FP)。就示踪剂之间的不一致情况而言:(1)1例患者,¹¹C-胆碱检查结果为FN但¹⁸F-FACBC检查结果为FP(淋巴结),(2)7例患者,¹¹C-胆碱检查结果为FN但¹⁸F-FACBC检查结果为TP(5例为淋巴结,1例为骨,1例为局部复发),(3)1例患者,¹¹C-胆碱检查结果为FP(淋巴结)但¹⁸F-FACBC检查结果为TP(局部复发),(4)2例患者,¹¹C-胆碱检查结果为FP(1例为淋巴结,1例为局部复发)但¹⁸F-FACBC检查结果为FN,(5)3例患者,¹¹C-胆碱检查结果为TP(2例为淋巴结,1例为骨)但¹⁸F-FACBC检查结果为FN。¹¹C-胆碱和¹⁸F-FACBC的敏感性分别为32%和37%,特异性分别为40%和67%,准确性分别为32%和38%,PPV分别为90%和97%,NPV分别为3%和4%。根据PSA水平对患者进行分类(<1 ng/ml共28例患者,1 - <2 ng/ml共28例患者,2 - <3 ng/ml共11例患者,≥3 ng/ml共22例患者),¹⁸F-FACBC检查结果为TP的患者数量(百分比)总体上高于¹¹C-胆碱:分别为6例患者(21%)和4例患者(14%),8例患者(29%)和8例患者(29%),5例患者(45%)和4例患者(36%),以及13例患者(59%)和11例患者(50%)。
在前列腺癌根治术后生化复发的患者中,¹⁸F-FACBC可被视为优于¹¹C-胆碱的一种替代示踪剂。